Our Publications
Click here for the complete list
Key publications of the last five years
2024
Diebold M, Vietzen H, Heinzel A, et al. Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation. Am J Transplant. 2024;24(5):743-754. doi:10.1016/j.ajt.2023.12.005
Regele F, Haupenthal F, Doberer K, et al. The kinetics of Torque Teno virus plasma load following calcineurin inhibitor dose change in kidney transplant recipients. J Med Virol. 2024;96(3):e29554. doi:10.1002/jmv.29554
2023
Herz CT, Diebold M, Kainz A, et al. Morphologic and Molecular Features of Antibody-Mediated Transplant Rejection: Pivotal Role of Molecular Injury as an Independent Predictor of Renal Allograft Functional Decline. Transpl Int. 2023;36:12135. Published 2023 Dec 19. doi:10.3389/ti.2023.12135
Haupenthal F, Rahn J, Maggi F, et al. A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT. Trials. 2023;24(1):213. Published 2023 Mar 22. doi:10.1186/s13063-023-07216-0
Böhmig GA, Halloran PF, Feucht HE. On a Long and Winding Road: Alloantibodies in Organ Transplantation. Transplantation. 2023;107(5):1027-1041. doi:10.1097/TP.000000000000455
Görzer I, Haupenthal F, Maggi F, et al. Validation of plasma Torque Teno viral load applying a CE-certified PCR for risk stratification of rejection and infection post kidney transplantation. J Clin Virol. 2023;158:105348. doi:10.1016/j.jcv.2022.105348
Borski A, Eskandary F, Haindl S, et al. Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Renal Allograft Rejection: Accumulation of Antibody-neutralized Interleukin-6 Without Signs of Proinflammatory Rebound Phenomena. Transplantation. 2023;107(2):495-503. doi:10.1097/TP.0000000000004285
2022
Mayer KA, Budde K, Jilma B, Doberer K, Böhmig GA. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials. Expert Opin Emerg Drugs. 2022;27(2):151-167. doi:10.1080/14728214.2022.2091131
Vietzen H, Döhler B, Tran TH, et al. Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant Outcome. Front Immunol. 2022;13:829228. Published 2022 Mar 24. doi:10.3389/fimmu.2022.829228
Mayer KA, Budde K, Halloran PF, et al. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials. 2022;23(1):270. Published 2022 Apr 8. doi:10.1186/s13063-022-06198-9
2021
Mayer KA, Doberer K, Tillgren A, et al. Diagnostic value of donor-derived cell-free DNA to predict antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients. Transpl Int. 2021;34(9):1689-1702. doi:10.1111/tri.13970
Doberer K, Duerr M, Halloran PF, et al. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2021;32(3):708-722. doi:10.1681/ASN.2020071106
Doberer K, Kläger J, Gualdoni GA, et al. CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. Transplantation. 2021;105(2):451-457. doi:10.1097/TP.0000000000003247
2020
Viklicky O, Krivanec S, Vavrinova H, et al. Crossing borders to facilitate live donor kidney transplantation: the Czech-Austrian kidney paired donation program - a retrospective study. Transpl Int. 2020;33(10):1199-1210. doi:10.1111/tri.13668
Mühlbacher J, Doberer K, Kozakowski N, et al. Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients. Front Med (Lausanne). 2020;7:114. Published 2020 Apr 9. doi:10.3389/fmed.2020.00114
Doberer K, Schiemann M, Strassl R, et al. Torque teno virus for risk stratification of graft rejection and infection in kidney transplant recipients-A prospective observational trial. Am J Transplant. 2020;20(8):2081-2090. doi:10.1111/ajt.15810
Doberer K, Bond G, Kläger J, et al. Immunoadsorption Combined with Membrane Filtration to Counteract Early Treatment-Refractory Antibody-Mediated Rejection. Blood Purif. 2020;49(5):576-585. doi:10.1159/000506504
2019
Mező B, Heilos A, Böhmig GA, et al. Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection. Transplant Direct. 2019;5(7):e470. Published 2019 Jun 27. doi:10.1097/TXD.0000000000000915
2018
Arnold ML, Kainz A, Hidalgo LG, et al. Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation. Am J Transplant. 2018;18(9):2261-2273. doi:10.1111/ajt.14710
Eskandary F, Regele H, Baumann L, et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2018;29(2):591-605. doi:10.1681/ASN.2017070818
Eskandary F, Jilma B, Mühlbacher J, et al. Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial. Am J Transplant. 2018;18(4):916-926. doi:10.1111/ajt.14528
2017
Wahrmann M, Mühlbacher J, Marinova L, et al. Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study. Am J Transplant. 2017;17(9):2300-2311. doi:10.1111/ajt.14256